Patients who do not respond to autologous stem cell transplantation (ASCT) have a poor prognosis. Concerns about toxicity limit the use of unrelated donor stem cell transplantation (UDSCT), but the knowledge about outcome after UDSCT post-ASCT is limited. We carried out a retrospective analysis of the outcome in seven consecutive patients with leukemia (n = 5), myeloma (n = 1) and graft failure (n = 1) who underwent UDSCT after ASCT. Donors were matched for HLA-A, -B and -DR (n = 6) or had one class I antigen mismatch (n = 1). Tissue typing was performed by a highresolution genomic technique for class II. Median patient age was 34 (11-54) years and time from ASCT to UDSCT was 16 (3-22) months. Patients with malignant diseases were given TBI and a CY preparatory regimen. In addition, all patients received T cell antibodies prior to UDSCT. Grade I acute GVHD developed in all seven patients, but there was no sign of more severe acute GVHD. Two of four evaluable patients developed limited chronic GVHD. Three died of transplant-related toxicity, all due to pulmonary complications. Four patients are alive at 1.1, 1.5, 3.1 and 4.9 years post-UDSCT. A closely matched UDSCT could be considered for selected patients who are not cured by an ASCT.
Patients with hematological malignancies who relapse after autologous stem cell transplantation (ASCT) have a poor outcome. 1, 2 Many are regarded as beyond cure and given low-dose regimens. However, a few are considered for a second transplant, either autologous or allogeneic. Since the anti-malignant characteristics of an allogeneic transplant are superior to those of an autologous transplant because of an immunologically mediated GVL reaction and no tumor contamination of the graft, the question often arises of whether an allogeneic transplant is too toxic or not indicated for patients who have already received intensive therapy. Occasionally, usually younger, patients are considered Correspondence: J Aschan, Department of Hematology, M54, Huddinge Hospital, S-141 86 Huddinge, Sweden Received 13 November 1998; accepted 11 March 1999 for allogeneic transplantation. In patients with graft failure after ASCT, an allogeneic transplant is the only hope of cure. Furthermore, since many of these patients have no suitable donor in the family, the only allogeneic alternative is an unrelated donor stem cell transplant (UDSCT).
In view of the increasing number of patients treated with ASCT, physicians are more frequently faced with the dilemma of how to manage relapse and graft failure after ASCT. Current knowledge of outcome after UDSCT in patients who relapse or have graft failure after ASCT is limited. Therefore, we analyzed toxicity, and incidence of relapse and survival in patients who underwent unrelated stem cell transplantation for relapse or graft failure after ASCT.
Materials and methods

Autologous transplantation
Seven patients were autografted for AML (n = 4), CML (n = 1), myeloma (n = 1) and Hodgkin's disease a median 7 months from diagnosis (range 5-22). Conditioning for ASCT consisted of BU in combination with CY (n = 4), BU + CY + etoposide (n = 1), the BEAM regimen (carmustine + etoposide + cytarabine + melphalan n = 1) and melphalan (n = 1, Table 1 ). No patients received TBI as preparation for ASCT. Five patients relapsed at a median of 10 months after ASCT, with a range of 3-17 months, one patient had progressive myeloma and one had graft failure.
Unrelated transplantation
Patients: Between January 1994 and October 1997, seven patients underwent UDSCT at Huddinge Hospital because they failed an ASCT. Patient age at the time of UDSCT was 34 years and the interval between two transplants was 16 months, range 3-22. All patients had satisfactory pulmonary, cardiac, hepatic and renal function (DLCO, FVC and FEV 1.0 Ͼ50%; left ventricular ejection fraction Ͼ45%; bilirubin Ͻ26 mol/l; creatinine Ͻ110 mol/l) prior to UDSCT. Data were analyzed retrospectively. Patient and donor characteristics are given in Tables 1 and  2 . HLA-typing was performed serologically in class I and with the PCR-SSP method in class II. 3 Details regarding patient care have been published elsewhere. [4] [5] [6] In summary, patients were kept in reverse isolation and given ciprofloxacin, co-trimoxazole and amphotericin B orally. Since May Cy + TBI UPN = unique patient number; UDSCT = unrelated donor stem cell transplantation; ASCT = autologous stem cell transplantation; Bu = busulfan; Cy = cyclophosphamide; BEAM = carmustine, etoposide, cytarabine, melphalan; TBI = total body irradiation. 1994, G-CSF has been given after the UDSCT. Pre-emptive therapy with ganciclovir or foscarnet was started after two consecutively positive tests for CMV DNA in PCR analyses. 7 Records were reviewed for evidence of complications, transplant-related mortality (death from all causes other than relapse or progression of the underlying hematological disease) and outcome. Results were analyzed as of 31 December 1998.
Conditioning:
Conditioning was given with our standard protocol, consisting of CY 120 mg/kg, combined with 10 Gy of TBI in a single fraction, with the lungs shielded to receive 9 Gy (n = 6). One patient was treated with fludarabine 35 mg/kg in a single dose in addition to CY 50 mg/kg on each of 4 successive days and 6 Gy fractionated splenic irradiation. All patients were given anti-thymocyte globulin (ATG, n = 6) 2-5 mg/kg/day or OKT-3 (n = 2) 5 mg/day for 5 (n = 6) or 10 (n = 1) days before transplantation.
GVHD: All patients were given a short course of MTX in combination with CsA as prophylaxis against GVHD. 4 MTX was given i.v. in a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11. CsA was started on day −1 in a dose of 5 mg/kg/day and lowered to 3 mg/kg/day on the day of transplantation. As soon as the patient could take CsA orally, 12.5 mg/kg/day was given via this route. During the first month, blood CsA levels were kept at 200-300 ng/ml. After 6 months, the CsA dose was lowered by 25% on alternate months and was discontinued after 12 months in the absence of GVHD. One patient with a class I antigen mismatched donor received in addition to MTX + CsA an in vitro T cell-depleted graft. T cells were depleted with monoclonal antibodies and magnetic beads. At the first sign of grade I acute GVHD, prednisolone 2 mg/kg/day was given for at least 1 week and thereafter tapered, depending on the response.
Results
Engraftment
Neutrophil engraftment occurred in all seven patients. The median day of ANC Ͼ0.5 × 10 9 /l was 22, with a range of 17-24 days. One patient had poor platelet engraftment and was successfully treated with 500 ml T cell-depleted booster marrow from the original donor, 5 months after UDSCT.
GVHD
All seven patients developed grade I acute GVHD, but none progressed to grade II. Limited chronic GVHD developed in two of four evaluable patients and was treated with CsA and prednisolone. Three patients died before day 90 and were not evaluable for chronic GVHD. 
Complications, survival and causes of death
Early complications included bacteremia in all seven patients and veno-occlusive disease of the liver in one patient who was treated with rh-tPA and recovered. Late non-fatal complications, in addition to chronic GVHD, were hemochromatosis and recurrent upper respiratory tract infections in one patient.
Four patients are alive 1.1, 1.5, 3.1 and 4.9 years after UDSCT ( Table 3 ). The actuarial probability of survival was 57% (Figure 1) . UPN 4 had a recurrence of chronic phase CML and was recently treated with donor lymphocyte infusions. UPN 2 had progressive myeloma, despite UDSCT. Three patients died on days 53, 61 and 86, two of idiopathic pneumonia with or without multi-organ failure, respectively, and one of aspergillosis.
Discussion
Patients with relapse or graft failure after ASCT have a poor prognosis.
1,2 Additional chemotherapy and/or radiation results in long-term survival in less than 10% of patients with relapsing lymphoma. 8 A second ASCT is less likely to cure patients relapsing after a first ASCT, since the anti-malignant properties are similar. However, an allogeneic SCT has the advantage of the GVL effect, an immunologically mediated anti-tumor reaction which has been shown in leukemias, myeloma and lymphoma. 9 Current knowledge about outcome after allogeneic SCT following ASCT is limited.
Tsai et al 10 reported the outcome for 20 patients from five institutions in the USA who underwent allogeneic bone marrow transplantation (allo-BMT) for relapse after autologous transplantation. An incidence of grade II-IV acute GVHD of 89% contributed to an 85% incidence of transplant-related mortality (TRM) and the survival of only three of 20 patients.
The European Group for Blood and Marrow Transplantation (EBMT) analyzed the outcome for 74 patients with relapsed acute leukemia who underwent allo-BMT after an autograft. 11 Most patients were given family mismatched or unrelated donor grafts. With a median follow-up of 7 months, 20 patients were alive, with a 2-year survival probability of 19%.
In our study all patients received grafts from unrelated donors, a procedure associated with a higher risk of TRM, than in HLA-identical sibling transplants. 12, 13 Despite this high-risk feature, four of seven patients survived. One explanation for the encouraging results could be the absence of moderate-to-severe acute GVHD. This, in turn, could reflect our use of anti-T cell antibodies in the preparatory regimen. We initially used ATG or OKT-3 to reduce the risk of graft rejection, but this probably also affected the risk of subsequent acute GVHD. 4 Furthermore, we already treat grade I acute GVHD with prednisolone, which could also influence the incidence of more severe GVHD.
The use of genomic class II typing might also have reduced the risk of GVHD.
The EBMT study reported that TBI in the conditioning for the first/autologous transplant was a risk factor for the second allogeneic transplant (Ringdén, personal communication) . In our study, no patient was given TBI before ASCT. This could have affected the result. Since the age distribution was similar to prior studies, this should not have done so. The limited number of patients in our study could also have influenced the results. Similar outcome was reported from another small single center study. 14 Three patients died, all from pulmonary problems within 3 months of UDSCT. Despite lung shielding during TBI, two patients developed idiopathic pneumonitis. Increasing the lung shield might reduce the risk of this complication. However, with a lower irradiation dose, the risk of relapse might increase. This risk might be counteracted by immunologic manipulation with cell therapy -ie infusion of donor lymphocytes, when a stable chimera is established.
In conclusion, our limited experience shows that UDSCT after ASCT can give a 57% probability of survival and could be considered for selected patients with relapse or graft failure after ASCT.
